Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as sirolimus, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Sometimes when chemotherapy is given, it does not stop the growth of tumor cells.
The tumor is said to be resistant to chemotherapy. Giving gefitinib together with sirolimus
may reduce drug resistance and allow the tumor cells to be killed.
PURPOSE: This phase I/II trial is studying the side effects and best dose of sirolimus when
given with gefitinib and to see how well they work in treating patients with recurrent or
refractory stage IIIB or stage IV non-small cell lung cancer.